Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2009;104:851-859
Published online before print February 26, 2009, doi: 10.1161/CIRCRESAHA.109.193805
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
104/7/851    most recent
CIRCRESAHA.109.193805v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szalay, G.
Right arrow Articles by Klingel, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szalay, G.
Right arrow Articles by Klingel, K.
Related Collections
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Myocardial cardiomyopathy disease
(Circulation Research. 2009;104:851.)
© 2009 American Heart Association, Inc.


Molecular Medicine

Osteopontin

A Fibrosis-Related Marker Molecule in Cardiac Remodeling of Enterovirus Myocarditis in the Susceptible Host

Gudrun Szalay, Martina Sauter, Michael Haberland, Ulrich Zuegel, Andreas Steinmeyer, Reinhard Kandolf, Karin Klingel

From the Department of Molecular Pathology (G.S., M.S., M.H., R.K., K.K.), Institute for Pathology, University Hospital, Tübingen; and Common Mechanism Research Berlin (U.Z.) and Medicinal Chemistry Berlin (A.S.), Global Drug Discovery, BayerSchering Pharma AG, Berlin, Germany.

Correspondence to Prof Dr Karin Klingel, Department of Molecular Pathology, University Hospital Tübingen, Liebermeisterstr. 8, D-72076 Tübingen, Germany. E-mail karin.klingel{at}med.uni-tuebingen.de


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The characteristics of dilated cardiomyopathy (DCM) resulting from chronic viral myocarditis are remodeling processes of the extracellular matrix. Based on our findings of enhanced osteopontin (OPN) expression in inflamed human hearts, we further investigated in the murine model of acute and chronic coxsackievirus (CV)B3-myocarditis the role of OPN regarding its involvement in resolution of cardiac virus infection and fibrosis. In hearts of A.BY/SnJ mice susceptible to chronic CVB3-myocarditis, a pronounced increase of OPN expression levels was detected by microarray analysis and quantitative RT-PCR during acute stages of myocarditis. Combined immunohistochemistry and in situ hybridization identified infiltrating macrophages as main OPN producers. In contrast to resistant C57BL/6 and OPN gene-deficient mice, transcription levels of matrix metalloproteinase-3, TIMP1 (tissue inhibitor of metalloproteinases-1), uPA (urokinase-type plasminogen activator), and transforming growth factor β1 were elevated in susceptible mice, and as a consequence, procollagen-1{alpha} mRNA expression and fibrosis was considerably enhanced. Treatment of infected susceptible mice with the vitamin D analog ZK 191784 led to decreased myocardial expression levels of OPN, metalloproteinase-3, TIMP1, uPA, and procollagen-1{alpha} and subsequently to reduced fibrosis. Concurrently, the fibrosis-relevant signaling molecules pERK (phosphorylated extracellular signal-regulated kinase) and pAkt (phosphorylated Akt), increased in A.BY/SnJ mice, were diminished in ZK 191784–treated mice. Here, we show that high expression levels of OPN in acute myocarditis are associated with consecutive development of extensive fibrosis that can be reduced by treatment with a vitamin D analog. Thus, OPN may serve as a diagnostic tool as well as a potential therapeutic target to limit cardiac remodeling in chronic myocarditis.


Key Words: myocarditis • infection • inflammation • remodeling • osteopontin


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Dilated cardiomyopathy (DCM), which is among the most common heart diseases, has various etiologies and clinical outcomes but is often a sequela of myocarditis and represents a major cause of morbidity and mortality worldwide. Up to 60% of patients with myocarditis and DCM are virus-positive.1 A critical step in development of DCM is the initiation of remodeling processes of the extracellular matrix. Pathological collagen synthesis leads to interstitial fibrosis and finally to cardiac dysfunction.2 Characteristics of DCM are left ventricular dilatation, a decreased ejection fraction, and a depressed wall motion attributable to fibrosis.2 This feature depicts the last stage of inflammatory heart disease, starting with acute myocarditis, passing to chronic myocarditis, and resulting in DCM.3,4

Viral infections of the heart have been associated with the development of DCM resulting from persistent infection and, consequently, chronic inflammatory processes following acute myocarditis.4,5 Among the cardiotropic viruses inducing myocarditis, enteroviruses, parvovirus B19, and human herpesvirus 6 represent the most commonly identified etiologic agents.5,6 Enteroviruses, especially coxsackieviruses of group (CV)B, belong to the best-studied pathogens evoking myocarditis. Recent studies demonstrate that the consequences of inflammatory responses in the heart caused by CVB3 infection play a decisive role in the development and progression of DCM.5,7,8 In the murine model of CVB3-induced myocarditis, it has been shown that CVB3 infection influences the regulation of extracellular matrix architecture via interference by inflammatory mediators.7,9 Proinflammatory cytokines such as interleukin (IL)-1β, IL-6, tumor necrosis factor-{alpha}, and transforming growth factor (TGF)β are involved in the regulation of matrix metalloproteinases (MMPs) and their inhibitors, TIMPs (tissue inhibitors of MMPs); the urokinase-type plasminogen activator (uPA); and connective tissue growth factor (CTGF). Disturbance of the fine balance of these factors contribute to cardiac fibrosis and hence to cardiac dysfunction and dilatation.9–11

More recently, another protein that has been described to be involved in inflammatory responses and in the maintenance or reconfiguration of tissue integrity, is osteopontin (OPN), a phosphorylated glycoprotein that exists as an immobilized matrix protein and as a cytokine.12 OPN is produced by a variety of cell types including fibroblasts, macrophages, and T cells and is expressed in a multitude of biological processes.13,14 The diverse functions of OPN comprise biomineralization, chemotaxis, support of adhesion, modulation of T-cell responses, cell survival, and wound repair.14 In the normal myocardium, OPN expression is absent but is increased under pathological conditions such as coronary heart disease, infarction, hypertrophy, and ischemia.15,16 Whereas a major source of OPN in the heart is probably interstitial fibroblasts, in inflammatory cardiac diseases macrophages can be added to the list of OPN producers.16

The expression of OPN is mediated by signaling via the vitamin D receptor.17 Transcriptional regulation of OPN is induced by the active vitamin D3 metabolite 1{alpha},25(OH)2D3, also known as calcitriol, whose association to the vitamin D3 receptor activates the binding of the vitamin D receptor 9-cis-retinoic acid receptor complex at the vitamin D response elements.17 Together with several coactivators, a multiprotein complex is built, which induces transcription of several genes among others is OPN and gene transcription can be enhanced by binding of calcitriol to G protein-coupled receptors.17,18 Besides other properties, calcitriol has profound effects on immunoregulation and its analog ZK 191784 has an immunosuppressive impact.19,20

The aim of the present study was to investigate the contribution of OPN to remodeling processes in enterovirus-induced myocarditis and subsequent DCM. We used the murine model of CVB3-induced myocarditis, in which susceptible A.BY/SnJ mice develop chronic myocarditis and severe cardiac fibrosis following acute infection resulting from a restricted type of virus persistence, whereas resistant C57BL/6 mice eliminate the virus during acute infection without evolving significant fibrosis.21 Additionally, we investigated the impact of OPN on the outcome of CVB3-induced myocarditis and its relationship with the development of fibrosis using OPN gene-deficient (OPN–/–) mice (see the online data supplement, available at http://circres.ahajournals.org). Furthermore, we pursued downregulation of OPN expression in CVB3-infected susceptible A.BY/SnJ mice by application of the vitamin D analog ZK 191784 and studied the consequences of OPN downregulation.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
In Situ Hybridization
Human OPN mRNA was detected in endomyocardial biopsies which were taken for diagnostic reasons with approval of the Ethics committee of the SFB-TR19. 35S-Labeled antisense and sense hOPN RNA probes were synthesized by in vitro transcription from the dual-promoter plasmid pGEM-hOPN containing a 350-bp cDNA fragment. Pretreatment, hybridization, and washing conditions of dewaxed 5-µm paraffin tissue sections were performed as described previously. Slide preparations were subjected to autoradiography and counterstained with hematoxylin/eosin.21

35S-Labeled antisense and sense RNA probes for detection of murine OPN mRNA were synthesized by in vitro transcription from the dual-promoter plasmid TOPO-mOPN containing an 879-bp OPN cDNA fragment. CVB3 positive-strand RNA was detected in tissues using single-stranded 35S-labeled RNA probes, which were synthesized from the dual-promoter plasmid pCVB3-R1. Control RNA probes were obtained from the vector pSPT18. Viral load was determined as previously described.8

Virus and Viral Antigens
CVB3 used in this study was derived from the infectious cDNA copy of the cardiotropic Nancy strain.22 Virus stocks and viral antigen preparation were prepared as described previously.8

Mice and Infection
C57BL/6 mice, ABY/SnJ mice, and OPN–/– mice (all H-2b) were purchased from The Jackson Laboratory. Animals were bred and kept under specific pathogen-free conditions at the animal facilities of the Department of Molecular Pathology, University Hospital Tübingen, and experiments were conducted according to the German animal protection law. Virus infection of mice and further processing of organs was performed as described previously.8

DNA Microarray Hybridization and Analysis
Isolation of RNA from murine heart tissue and microarray analysis from Affymetrix (Santa Clara, Calif) MG-U74Av2 chips was performed by application of the Affymetrix gene expression software GeneChip, MicroDB, and Data Mining Tool as described previously.23

RT-PCR and Quantitative RT-PCR
Specific primers and probes were purchased from MWG Biotech. Primers were as follows:

In the first experiments for the evaluation of real-time RT-PCR, we compared mRNA expression from individual mice (n=5) in comparison with pooled mRNA from 5 mice to obtain information on the individual variation of expression levels in the different mouse strains. Because the expression variations of individual mRNA within 1 mouse strain were minimal and the mean values similar to pooled mRNA, we decided to use pooled mRNA for our experiments.23

Determination of Cytokines by ELISA
Determination of interferon (IFN){gamma} and IL-10 levels was performed as previously described.8

Histology and Immunohistochemical Staining
Histology and quantification of myocardial damage was performed as previously described.8 For immunohistochemistry, tissue sections were incubated for 1 hour at 25°C with goat anti-mouse antibodies recognizing murine OPN (R&D), rabbit antihuman OPN (Neomarker), with rat anti-mouse antibody recognizing Mac-3 (Becton Dickinson) on macrophages and with rabbit anti-mouse antibody recognizing CD3 (Neomarker) on T lymphocytes, respectively. Controls using normal goat, rabbit, or rat serum were run to exclude nonspecific staining. Slides were processed using streptABComplexHRP (DAKO) and DAB (Vector Laboratories) as substrate. Quantification was assessed as number of positive cells per square millimeter myocardial lesion.21 For evaluation of fibrosis, picrosirius red staining was applied.

Concurrent Immunohistochemistry and In Situ Hybridization
For identification of OPN positive cells, tissue sections were processed by immunohistochemistry to detect Mac-3+ macrophages followed by in situ hybridization (ISH) to demonstrate OPN mRNA expression as described previously.24

Treatment With Vitamin D Analog ZK 191784
Mice were treated with 100 µg/kg the vitamin D analog ZK 191784 (a kind gift from Bayer Schering Pharma AG) subcutaneously 1 day before infection until day 12 postinfection (pi). CVB3 infection was performed as described above and mice were euthanized at day 8, day 12, and day 28 pi. As controls, ZK 191784–treated, uninfected mice as well as untreated, CVB3-infected mice were used. At indicated time points, hearts were removed and subjected to the investigations described above.

Statistical Analysis
When statistical analysis was performed, data were expressed as means±SEM. Significance was calculated by use of Mann-Whitney U test or unpaired t test using SPSS 11.0 software as indicated in the figure legends. An probability of P<0.05 was regarded as significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
OPN Expression in Human Endomyocardial Biopsies With Chronic Myocarditis
We received first evidence that OPN might be relevant in the pathogenesis of chronic myocarditis when we performed in situ hybridization experiments and immunohistological stainings for visualization of OPN mRNA and protein in human endomyocardial biopsies. As exemplary illustrated in heart tissue sections from patients with histopathologically proven chronic myocarditis, we found a significant number of OPN mRNA (Figure 1A, arrows), as well as OPN protein-expressing cells (Figure 1B, arrows) in the interstitium of the myocardium. Clusters of OPN mRNA-positive mononuclear cells (Figure 1A), most probably representing macrophages, were found to be mainly located within areas of inflammation. In cardiac tissue of patients with DCM where an interstitial inflammatory response is usually absent, no significant OPN mRNA (Figure 1C) and protein (Figure 1D) expression was detected in cardiomyocytes or interstitial cells.


Figure 1
View larger version (124K):
[in this window]
[in a new window]

 
Figure 1. Visualization of OPN mRNA (A) and protein (B) expression in mononuclear inflammatory cells within cardiac lesions by in situ hybridization in an endomyocardial biopsy of a patient with chronic viral myocarditis. In patients with DCM, no OPN mRNA (C) and protein (D) expression was observed.

Expression Patterns of OPN in Murine Hearts in CVB3-Myocarditis
To gain further insight into OPN expression at different stages of myocarditis, we examined different CVB3-infected mouse strains. Highly upregulated OPN mRNA expression levels in infected mouse hearts were first noted in experiments identifying differential gene expression patterns by whole-genome microarray analysis using Affimetrix chips.23 During the acute phase of CVB3 infection, OPN mRNA expression was upregulated in the hearts of C57BL/6 mice undergoing mild acute myocarditis, as well as in A.BY/SnJ mice susceptible to severe acute and chronic myocarditis. Importantly, A.BY/SnJ mice revealed approximately 4 times higher expression levels than C57BL/6 mice during the acute phase of infection (Figure 2A). To further evaluate these findings, we performed quantitative RT-PCR of CVB3-infected A.BY/SnJ and C57BL/6 mouse hearts at day 4 pi (an early time point of infection), during the acute phase of myocarditis (day 8 and day 12 pi), and at day 28 pi when chronic myocarditis is established in A.BY/SnJ mice. As shown in Figure 2B and 2C, OPN mRNA expression was induced in the heart of both mouse strains after CVB3 infection with a peak during the acute phase of myocarditis, revealing more than 100-fold higher expression in susceptible mice. Thereafter, the OPN expression declined in both mouse strains until day 28 pi. In turn, the highly enhanced OPN mRNA expression in hearts of susceptible mice compared to resistant mice was detectable throughout the investigated time schedule (note the different scaling in Figure 2B and 2C). Determination of OPN protein in sera revealed a slightly higher secretion in susceptible mice; however, the clear differences seen in the heart were not reflected by sera concentrations (data not shown), stressing the importance of analyzing the local situation in inflamed hearts.


Figure 2
View larger version (17K):
[in this window]
[in a new window]

 
Figure 2. Enhanced OPN expression in hearts of CVB3-infected susceptible mice. Comparison of OPN mRNA expression of CVB3-infected susceptible A.BY/SnJ and resistant C57BL/6 mice at days 4, 8, and 28 pi obtained by microarray analysis (A) and quantitative RT-PCR analysis (B and C). At day 8 pi, the maximum of OPN mRNA expression was detected with distinct higher levels in susceptible mice compared to resistant mice (note the different scaling in B and C). mRNA was pooled from 5 animals per mouse strain and experiments were repeated twice.

In the myocardium, OPN mRNA expression was spatially correlated with CVB3 RNA expression by ISH, as demonstrated in consecutive transverse heart tissue sections of the left and right ventricle (Figure 3A). OPN mRNA expression was present within areas of cardiac infiltrates in A.BY/SnJ mice and C57BL/6 mice and was found to correlate well with CVB3-positive areas within consecutive myocardial tissue sections (Figure 3B, I+II and IV+V). In situ hybridization further demonstrated that at the cellular level the macrophages of ABY/SnJ mice express more OPN mRNA than those of C57BL/6 mice, suggesting that major histocompatibility complex-independent genetic factors influence OPN expression. In addition, as shown by immunohistochemistry in Figure 3B, III and VI, in susceptible mice, considerably more OPN protein expression per area fraction of cardiac lesions was found than in resistant mice, confirming the results of OPN mRNA expression. In the course of CVB3-myocarditis, first macrophages and then T cells infiltrate the myocardium.24 By using a double-labeling technique with ISH and immunohistochemistry to identify OPN-expressing cell types, macrophages (Mac-3–positive) were identified as the main source of OPN mRNA expression in the heart of CVB3-infected animals (Figure 3C, I+II). ISH with control RNA probes did not reveal unspecific binding to labeled macrophages (Figure 3C, III) and also double labeling using isotype controls and uninfected myocardium gave negative results (data not shown). Hence, infiltrating cardiac macrophages were identified as major OPN-secreting cells in CVB3-myocarditis.


Figure 3
View larger version (102K):
[in this window]
[in a new window]

 
Figure 3. OPN is expressed by infiltrating macrophages in vicinity to CVB3-infected myocytes. Detection of CVB3 RNA and OPN mRNA in hearts of infected mice (A and B, I, II, IV, and V) by ISH and immunohistological staining of OPN within inflammatory lesions (A, III and VI). Combined ISH and immunohistochemistry identified macrophages as main OPN-expressing cells in the myocardium of CVB3-infected animals (C, I and II). ISH with unrelated control RNA probes revealed no specific binding of 35S-labeled probes following immunohistochemical labeling of macrophages (C, III).

OPN Is Not Involved in the Resolution of Myocarditis
Because OPN can modulate T cell-dependent immune responses by acting as a chemokine and attracting T cells to the site of infection,25 we included OPN–/– C57BL/6 mice in our study. As a result, the composition and number of infiltrating macrophages and T cells per square millimeter inflammatory lesion were found to be comparable in hearts of OPN–/– and OPN+/+ C57BL/6 mouse strains. In addition, OPN–/– mice were found to eliminate cardiac virus infection during acute myocarditis, indicating that OPN is not required to induce an effective immune response for the resolution of CVB3 infection. This observation is supported by the finding that the effective secretion of the protective cytokines IFN{gamma} and IL-10 in OPN–/– mice reflects the typical patterns observed in resistant mice (see the expanded text and figures in the online data supplement).

OPN in Cardiac Remodeling Processes in Chronic CVB3-Myocarditis
Remodeling processes of cardiac extracellular matrix in the course of chronic CVB3-myocarditis are known to be associated with the expression of MMPs and TIMPs.9 The interplay between these factors contributes to the development of fibrosis in the inflamed heart. MMPs and especially MMP3 are well-known targets for OPN. To evaluate the relationship of MMP, TIMP, and OPN in CVB3-myocarditis, we compared cardiac MMP3 and TIMP1 expression in susceptible A.BY/SnJ mice and in resistant C57BL/6 mice. In susceptible mice, MMP3 mRNA expression was pronounced at day 8 and day 12 pi and also TIMP1 mRNA was highly expressed at day 8 pi, as determined by quantitative RT-PCR, whereas in resistant mice, a distinct lower expression of MMP3 and TIMP1 in the course of myocarditis was noted (Figure 4). Recently, it was shown that an additional factor important for degradation of interstitial matrix in myocarditis is the uPA.10 We found that transcript levels of uPA were elevated during acute myocarditis (8 and 12 days pi) in susceptible mice, whereas uPA mRNA expression was only minimally increased at day 8 pi in resistant mice (Figure 4). Next, we examined TGFβ1 mRNA levels, because TGFβ1 is known to be involved in the signal transduction cascade of OPN inducing fibrosis.26 In A.BY/SnJ mice, TGFβ1 mRNA expression was induced after CVB3 infection with a maximum at day 8 pi, whereas in C57BL/6 mice, only basal TGFβ1 expression could be detected throughout infection (Figure 4). Altogether, OPN associated fibrosis-related molecules were higher expressed in susceptible mice than in resistant mice. The results obtained in resistant mice were confirmed in OPN–/– mice (see Figures I and II in the online data supplement).


Figure 4
View larger version (22K):
[in this window]
[in a new window]

 
Figure 4. High expression of fibrosis-inducing molecules in susceptible mice compared to resistant mice. From hearts of infected A.BY/SnJ and C57BL/6 mice and uninfected control mice, RNA was isolated at indicated time points and was tested for mRNA expression of MMP3, TIMP1, uPA, and TGFβ by quantitative RT-PCR. RNA was pooled from 5 animals per mouse strain and experiments were repeated twice with similar results.

Consequences of Treatment With the Vitamin D Analog ZK 191784
To investigate whether downregulation of OPN expression can reduce CVB3-induced fibrosis, we applied the vitamin D analog ZK 191784 in susceptible A.BY/SnJ mice, because OPN transcription is mediated through signaling via the vitamin D receptor.17 By determination of area fractions of infection by ISH in hearts, we examined the influence of ZK 191784 on viral load and found no difference between the untreated and treated group (23925±2419 µm2/mm2 in CVB3 infected A.BY/SnJ mice versus 23025±1658 µm2/mm2 in treated animals 8 days pi), indicating that ZK 191784 does not influence virus replication. From hearts of CVB3-infected, ZK 191784–treated mice (day 8 pi), we performed quantitative RT-PCR to determine OPN, MMP3, TIMP1, and uPA mRNA expression, because at this time point, maximal RNA expression of these molecules was detectable in A.BY/SnJ mice. In CVB3-infected ZK 191784–treated A.BY/SnJ mice OPN mRNA expression was significantly diminished (P<0.05) compared to infected, untreated A.BY/SnJ mice and was accompanied by reduced MMP3, TIMP1, and uPA mRNA expression (Figure 5). Uninfected A.BY/SnJ mice treated with the analog showed the same expression levels of measured molecules such as uninfected controls and were used for calculation of the relative expression levels of treated mice.


Figure 5
View larger version (15K):
[in this window]
[in a new window]

 
Figure 5. Decreased expression of fibrosis-inducing molecules in susceptible mice after treatment with a vitamin D analog. At day 8 pi, the time point of maximal OPN mRNA expression, treatment of susceptible A.BY/SnJ mice with ZK 191784 significantly reduced mRNA expression of OPN, MMP3, TIMP1; expression of uPA mRNA was close to significance (P=0.07). Significance was determined by using unpaired t test.

Because vitamin D receptor and G protein-coupled receptors signal via the MAPK-ERK pathway, we examined ERK expression in hearts of infected susceptible and resistant mice as well as in ZK 191784–treated A.BY/SnJ mice by immunohistochemistry. Phosphorylated ERK (pERK) expression was distinctly enhanced in hearts of susceptible mice compared to resistant mice (Figure 6A, I and III) and application of the vitamin D analog reduced pERK expression in infected hearts (Figure 6A, II), possibly contributing to the diminished OPN transcription. One consequence of diminished OPN transcription may be less signaling via the OPN receptors integrin {alpha}vβ3 and CD44. OPN receptor signaling is conferred via the MAPK-ERK and also via the phosphorylated Akt (pAkt) pathway. To delineate these pathways in our myocarditis model, we performed immunohistochemical staining for pAkt in hearts of ZK 191784–treated and untreated A.BY/SnJ mice (Figure 6B). Cardiac pAkt expression was highest in susceptible A.BY/SnJ mice (Figure 6B, I), while resistant mice (Figure 6B, III) showed moderate expression and treated mice (Figure 6B, II) were intermediate. Control stainings with the respective irrelevant antibodies were negative (Figure 6A, IV, and 6B, IV).


Figure 6
View larger version (92K):
[in this window]
[in a new window]

 
Figure 6. Diminished expression of signal-transducing molecules pERK and pAkt in susceptible mice after treatment with a vitamin D analog. In hearts of susceptible A.BY/SnJ mice, prominent expression of pERK (A, I) and pAkt (B, I) was detected. In contrast, in ZK 191784–treated A.BY/SnJ mice (A+B, II) or C57BL/6 mice (A+B, III), only moderate expression of both molecules was detectable. Controls without primary antibody were negative (A+B IV).

Fibrosis in CVB3-Infected Resistant, Susceptible, and ZK 191784–Treated Mice
To study the impact of OPN expression on the development of fibrosis, we analyzed the expression of procollagen type 1 {alpha} in the hearts of infected animals as an indicator for collagen synthesis and examined the extent of fibrosis in the hearts of resistant, susceptible and ZK 191784–treated susceptible mice. At day 8 pi, mRNA expression of procollagen 1 {alpha} was similar in all mice; thereafter, expression was low in C57BL/6 mice throughout the investigated time points, whereas in susceptible A.BY/SnJ mice, procollagen levels reached a maximum at day 12 pi and thereafter declined (Figure 7A). ZK 191784–treated animals showed reduced procollagen levels at days 12 and 28 pi, although treatment was pursued only for 12 days pi. As a consequence of high procollagen expression, extended areas of fibrosis were detected in the hearts of A.BY/SnJ mice compared to hearts of resistant C57BL/6 mice, which only showed minor replacement fibrosis, as shown by picrosirius red stainings (Figure 7B). A reduction of fibrosis was also noted in ZK 191784–treated animals at later stages of myocarditis (day 28 pi).


Figure 7
View larger version (72K):
[in this window]
[in a new window]

 
Figure 7. Extensive fibrosis develops in susceptible mice but not in resistant mice or susceptible mice treated with a vitamin D analog. Compared to C57BL/6 or ZK 191784–treated A.BY/SnJ mice, procollagen 1{alpha} mRNA expression was enhanced in susceptible A.BY/SnJ mice at day 12 pi (A). RNA was pooled from 3 to 5 animals per mouse strain and experiments were repeated twice. A considerable replacement fibrosis was detected only in susceptible mice but not in C57BL/6 or ZK 191784–treated A.BY/SnJ mice at day 28 pi (B).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
Based on our findings of OPN expression in human hearts undergoing chronic myocarditis but not DCM, we aimed to investigate the impact of OPN for remodeling processes in murine acute and chronic CVB3-myocarditis. We found during acute disease high levels of OPN in CVB3-infected mice susceptible to chronic myocarditis, whereas in resistant C57BL/6 mice undergoing only mild acute myocarditis, OPN expression was only moderate. OPN transcription is mediated via the vitamin D receptor and G protein-coupled receptors, which signal via the MAPK-ERK pathway. In addition, it is most likely that CVB3 infection contributes to enhanced OPN transcription, as CVB3 is reported to phosphorylate ERK with higher activation levels in susceptible mice than in resistant mice.27 This notion was strengthened by our findings of reduced pERK expression in CVB3-infected susceptible mice by inhibition of vitamin D signaling.

The consequences of this high OPN expression may result in diverse implications, because OPN is involved in modulating immune responses as well as in fibrosis development.13,14,28 Concerning its role in the immune system, OPN might function as a protective chemokine, important for the attraction of macrophages and T cells to areas of infection. However, as previously reported for influenza virus or vaccinia virus infection,29 also in our model system, OPN was found not to be necessary for mounting an appropriate antiviral immune response. OPN-independent attraction of T cells and macrophages into the immunized heart was also observed in autoimmune myocarditis.30 Additionally, we found that OPN–/– mice were able to overcome cardiac infection during acute disease, thus preventing chronic myocarditis, which can be attributed very likely to an effective production of the protective cytokines IFN{gamma} and IL-10, a finding which we already defined as resistance factors in immunocompetent C57Bl/6 mice.8 Importance of adequate cytokine secretion was also proven in herpes simplex virus type 1–infected OPN–/– mice, in which an impaired immune response was assigned to deregulated secretion of IL-12 and IL-10, as well as reduced IFN{alpha} production by plasmacytoid dendritic cells.31 In conclusion, our data suggest that OPN does not interfere with the antiviral immunity in CVB3-infected mice.

Concerning the evolvement of fibrosis associated with chronic inflammation, we investigated the contribution of OPN to cardiac remodeling processes as increased OPN expression is known to correlate with other fibrotic diseases, for example, with murine and human pulmonary fibrosis.32,33 Fibrosis following chronic myocarditis is a consequence of continuous influx of inflammatory cells triggered by persistent heart muscle infection.21 In our ISH experiments for the detection of OPN mRNA, macrophages were identified as major producers of OPN, whereas in human DCM, cardiomyocytes have been suggested as relevant OPN expressing cells.34,35 In our model system, there is a firm temporal and spatial correlation between invasion of macrophages early in enterovirus myocarditis and OPN expression. These observations are in agreement with findings in autoimmune myocarditis of rats, where OPN is expressed early after induction of inflammation, with CD11b+ inflammatory monocytes as the main OPN-producing cell population.36,37

OPN is known to induce uPA, MMPs, and TIMPs, all molecules that have recently been shown to play a major role in cardiac injury, dysfunction, and fibrosis in viral myocarditis.10,38 Here, we demonstrate a high expression of these extracellular matrix molecules in CVB3-infected susceptible A.BY/SnJ mice during acute disease, whereas minor expression was detected in resistant C57BL/6 mice, OPN–/– mice and ZK 191784–treated A.BY/SnJ mice. Induction of these fibrosis relevant molecules was found to be dependent on the contribution of OPN signaling via its receptor {alpha}vβ3 integrin.28 Integrins use multiple signaling pathways including the phosphatidylinositol 3-kinase/Akt cascade and the MEK-ERK cascade.39 In CVB3-infected hearts of OPN–/– mice, pAkt and also pERK expression was less pronounced in OPN–/– mice than in resistant C57BL/6 mice. For pERK activation, our results in susceptible mice point to 2 ways that might be operative for its activation: first, the enhancement via vitamin D signaling, leading to pronounced OPN expression; and second, the subsequent enhancement via OPN signaling. Because the OPN-ERK-Elk1 pathway, as well as the phosphatidylinositol 3-kinase cascade, is well known to enhance type I collagen expression, it can be concluded that OPN contributes to the development of heart fibrosis in CVB3-infected animals.40,41

In conclusion, OPN might represent a valuable tool to predict the evolvement of DCM following chronic myocarditis, and inhibition of OPN expression by using a vitamin D analog might be a therapeutic option to reduce cardiac fibrosis and remodeling.


*    Acknowledgments
 
We thank Sandra Bundschuh, Carmen Ruoff, and Renate Junghans for excellent technical assistance.

Sources of Funding

This work was supported by Deutsche Forschungsgemeinschaft grant SFB-TR19, Bundesministerium für Bildung und Forschung grant 01EZ0817, and the Dr Karl-Kuhn-Stiftung (to K.K.).

Disclosures

None.


*    Footnotes
 
Original received May 9, 2008; resubmission received January 8, 2009; revised resubmission received February 4, 2009; accepted February 17, 2009.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003; 60: 5–10.[Abstract/Free Full Text]

2. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P. van de Werf F, Pinto Y, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation. 2005; 112: 1136–1144.[Abstract/Free Full Text]

3. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart. 1997; 78: 539–543.[Abstract/Free Full Text]

4. Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R. Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol. 2004; 193: 101–107.[CrossRef][Medline] [Order article via Infotrieve]

5. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, Lindinger A, Böhm M. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008; 118: 639–648.[Abstract/Free Full Text]

6. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006; 114: 1581–1590.[Abstract/Free Full Text]

7. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJ, Njoku DB, Rose NR. Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol. 2004; 165: 1883–1894.[Abstract/Free Full Text]

8. Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R, Klingel K. Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol. 2006; 169: 2085–2093.[Abstract/Free Full Text]

9. Li J, Schwimmbeck PL, Tschope C, Leschka S, Husmann L, Rutschow S, Reichenbach F, Noutsias M, Kobalz U, Poller W, Spillmann F, Zeichhardt H, Schultheiss HP, Pauschinger M. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res. 2002; 56: 235–247.[Abstract/Free Full Text]

10. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto YM. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation. 2006; 114: 565–573.[Abstract/Free Full Text]

11. Lang C, Sauter M, Szalay G, Racchi G, Grassi G, Rainaldi G, Mercatanti A, Lang F, Kandolf R, Klingel K. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. J Mol Med. 2008; 86: 49–60.[CrossRef][Medline] [Order article via Infotrieve]

12. Graf K, Stawowy P. Osteopontin: a protective mediator of cardiac fibrosis? Hypertension. 2004; 44: 809–810.[Free Full Text]

13. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000; 81: 373–390.[CrossRef][Medline] [Order article via Infotrieve]

14. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin-a molecule for all seasons. Q J Med. 2002; 95: 3–13.

15. O'Brien ER, Garvin MR, Steward DK, Hinohara T, Simpson JB, Schwartz SM, Gaichelli CM. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994; 14: 1648–1656.[Abstract/Free Full Text]

16. Tamura A, Shingai M, Aso N, Hazuku T, Nasu M. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J. 2003; 67: 742–744.[CrossRef][Medline] [Order article via Infotrieve]

17. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7: 684–700.[CrossRef][Medline] [Order article via Infotrieve]

18. Haussler MR, Whitfield GK, Haussler CA, Hsieh J-C, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998; 13: 325–349.[CrossRef][Medline] [Order article via Infotrieve]

19. May E, Asadullah K, Zügel U. Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy. 2004; 4: 377–393.

20. Zügel U, Steinmeyer A, Giesen C, Asadullah K. A novel immunosuppressive 1{alpha},25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity. J Invest Dermatol. 2002; 119: 1434–1442.[CrossRef][Medline] [Order article via Infotrieve]

21. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA. 1992; 89: 314–318.[Abstract/Free Full Text]

22. Kandolf R, Hofschneider PH. Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc Natl Acad Sci USA. 1985; 82: 4818–4822.[Abstract/Free Full Text]

23. Szalay G, Meiners S, Voigt A, Lauber J, Spieth C, Speer N, Sauter M, Kuckelkorn U, Zell A, Klingel K, Stangl K, Kandolf R. Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes. Am J Pathol. 2006; 168: 1542–1552.[Abstract/Free Full Text]

24. Klingel K, Stephan S, Sauter M, Zell R, McManus BM, Bültmann B, Kandolf R. Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J Virol. 1996; 70: 8888–8895.[Abstract]

25. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287: 860–864.[Abstract/Free Full Text]

26. Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P, Liaw L, Schmidt R, Shankland SJ, Alpers CE, Couser WG, Johnson RJ. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999; 56: 571–580.[CrossRef][Medline] [Order article via Infotrieve]

27. Opavsky MA, Martino T, Rabinovitch M, Penninger J, Richardson C, Petric M, Trinidad C, Butcher L, Chan J, Liu PP. Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest. 2002; 109: 1561–1569.[CrossRef][Medline] [Order article via Infotrieve]

28. Scatena M, Liaw L, Giachelli CM. Osteopontin a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007; 27: 2302–2309.[Abstract/Free Full Text]

29. Abel B, Freigang S, Bachmann MF, Boschert U, Kopf M. Osteopontin is not required for the development of Th1 responses and viral immunity. J Immunol. 2005; 175: 6006–6013.[Abstract/Free Full Text]

30. Abel B, Kurrer M, Shamshiev A, Marty RR, Eriksson U, Günthert U, Kopf M. The osteopontin-CD44 pathway is superfluous for the development of autoimmune myocarditis. Eur J Immunol. 2006; 36: 1–6.[CrossRef]

31. Shinohara ML, Lu L, Bu J, Werneck MBF, Kobayashi KS, Glimcher LH, Cantor H. Osteopontin expression is essential for interferon-{alpha} production by plasmacytoid dendritic cells. Nat Immunol. 2006; 7: 498–506.[CrossRef][Medline] [Order article via Infotrieve]

32. Nakama K, Miyazaki Y, Nasu M. Immunophenotyping of lymphocytes in the lung interstitium and expression of osteopontin and interleukin-2 mRNAs in two different murine models of pulmonary fibrosis. Exp Lung Res. 1998; 24: 57–70.[Medline] [Order article via Infotrieve]

33. Pardo A, Gibson K, Cisneros J, Richards TH, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, Kaminski N. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PloS Med. 2005; 2: 891–903.

34. Stawowy P, Blaschke F, Pfautsch P, Goetze S, Lippek F, Wollert-Wulf B, Fleck E, Graf K. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail. 2002; 4: 139–146.[Abstract/Free Full Text]

35. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail. 2005; 7: 755–762.[Abstract/Free Full Text]

36. Hanawa H, Abe S, Hayashi M, Yoshida T, Yoshida K, Shiono T, Fuse K, Ito M, Tachikawa H, Kashimura T, Okura Y, Kato K. Kodama M, Maruyama S, Yamamoto T, Aizawa Y. Time course of gene expression in rat experimental autoimmune myocarditis. Clin Sci. 2002; 103: 623–632.[Medline] [Order article via Infotrieve]

37. Yoshida T, Hanawa H, Toba K, Watanabe H, Watanabe R, Yoshida K, Abe S, Kato K, Kodama M, Aizawa Y. Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res. 2005; 68: 278–288.[Abstract/Free Full Text]

38. Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC. Osteopontin: it’s role in regulation of cell motility and nuclear factor {kappa}B-mediated urokinase type plasminogen activator expression. IUBMB Life. 2005; 57: 441–447.[CrossRef][Medline] [Order article via Infotrieve]

39. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999; 285: 1028–1032.[Abstract/Free Full Text]

40. Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, Scanga A, Brenner DA, Rippe RA. The role of focal adhesion kinase-phosphatidylinositol 3 kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem. 2003; 278: 8083–8090.[Abstract/Free Full Text]

41. Wu CC, Li YS, Haga JH, Wang N, Lian IY, Su FC, Usami S, Chien S. Roles of MAP kinases in the regulation of bone matrix gene expressions in human osteoblasts by oscillatory fluid flow. J Cell Biochem. 2006; 98: 632–641.[CrossRef][Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
H. Luo, J. Wong, and B. Wong
Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy
Cardiovasc Res, August 6, 2009; (2009) cvp225v2.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
104/7/851    most recent
CIRCRESAHA.109.193805v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szalay, G.
Right arrow Articles by Klingel, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szalay, G.
Right arrow Articles by Klingel, K.
Related Collections
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Myocardial cardiomyopathy disease